Kurumaji Y, Shono M
Department of Dermatology, Saiseikai Kawaguchi General Hospital, Japan.
Dermatology. 1994;188(2):117-21. doi: 10.1159/000247114.
We describe the first case of drug-induced solar urticaria due to repirinast, an antiallergic drug developed and introduced into the market in Japan in 1987. The patient was a 72-year-old woman who had been on repirinast for 1 year and 8 months. She developed urticaria immediately after an irradiation with 1.5 J/cm2 of UVA, and the provocation test confirmed that repirinast was responsible for the urticarial reaction. The action spectrum of the urticarial reaction was deduced to be 320-350 nm. Passive and reverse passive transfer test results were both negative. However, intradermal injection of patient serum, obtained while she was on repirinast and irradiated in vitro with UVA, demonstrated positive reactions both in the patient and in a normal volunteer. Our findings suggest that nonallergic mechanisms are involved in the reaction. However, the rarity of the phenomenon also suggests an association with some allergic mechanisms.
我们描述了首例由瑞吡司特引起的药物性日光性荨麻疹病例。瑞吡司特是一种抗过敏药物,于1987年在日本研发并投放市场。患者为一名72岁女性,服用瑞吡司特已有1年零8个月。她在接受1.5 J/cm2的UVA照射后立即出现荨麻疹,激发试验证实瑞吡司特是导致荨麻疹反应的原因。推断荨麻疹反应的作用光谱为320 - 350 nm。被动和反向被动转移试验结果均为阴性。然而,皮内注射患者在服用瑞吡司特期间采集的血清,并在体外接受UVA照射后,患者和一名正常志愿者均出现阳性反应。我们的研究结果表明该反应涉及非过敏机制。然而,这种现象的罕见性也提示与某些过敏机制有关。